Global Momentum: BOT/BAL Across Borders | Agenus Stakeholder Briefing – October 2025 Peter Dinklage [aeP3GyqvH6F]
Tag: #Peter Dinklage, #fc barcelona, #audi q9, #canadian housing market trends
This October 2025 Stakeholder Briefing features new data from ESMO 2025 and international access milestones advancing Agenus' vision bmw alpina reveal immunotherapy combination, botensilimab (BOT) and balstilimab (BAL) for patients with hard-to-treat cancers.
Featured Speakers:
Dr. Michael Gordon, Chief Medical Officer, HonorHealth Research Institute reviews updated Phase 1b pan-tumor data presented at ESMO 2025, spanning more than 400 patients with refractory solid tumors.
Professor social security trust fund deficit Alexander Eggermont, global immuno-oncology expert and former Director General of Gustave Roussy Cancer Center (France) discusses Frances AAC program and BOT/BALs amal clooney inclusion for refractory MSS colorectal cancer, a landmark step in expanding access to patients beyond the U.S.
Q&A
Discover how Agenus is building global momentum for BOT/BAL driving durable responses in cold tumors historically unresponsive to checkpoint inhibitors and advancing pathways for patient access worldwide.